Wearable Injector Market

Wearable Injector Market Outlook (2024 to 2034)

Worldwide revenue from wearable injector sales is estimated to reach US$ 8.35 billion in 2024. The global wearable injector market size has been analyzed to climb to a value of US$ 29.64 billion by the end of 2034, expanding at a remarkable CAGR of 13.5% over the next ten years (2024 to 2034).

A wearable injector is a type of medical device used to administer drugs or other medications under the skin under strict control. The device is discreetly and conveniently worn on the body as a small pump or patch for drug administration.

On-body injectors in wearable injectors provide long-lasting therapeutic effects, which improve patient compliance and treatment efficacy. By making the administration process simpler, wearable injectors with a large volume have been shown to increase medication adherence. Many dosing options are available with the sophisticated wearable injection device, including basal, bolus, and continuous delivery.

Key Market Growth Drivers

• Most wearable injectors have connectivity features that let them work with healthcare monitoring systems or mobile apps. This leads to improved management and individualized care by enabling medical professionals to remotely monitor patient adherence, dosing patterns, and overall treatment progress, thus contributing to the expansion of the wearable injector market size.
• Wearable injectors ensure accurate delivery of the prescribed dosage by providing precise and controlled medication dosing. They have safety features such as mechanisms to prevent accidental needle stick injuries or automatic needle retraction.
• These devices are becoming more and more popular in labs, diagnostic centers, and clinics as they are less expensive than other controlled-delivery devices.
• Advancements in wearable, highly sensitive, and multifunctional strain sensors have made it possible to introduce wearable human interface devices for a range of applications, including intelligent robotics, wearable therapies, and healthcare monitoring. The rising adoption of sterile injectable drugs also supports market growth.
• The pharmaceutical industry has seen significant technological advancements with the introduction of enhanced drug delivery devices such as wearable injectors, auto-injectors, and pen injectors.

Report Attribute	Detail
Wearable Injector Market Size (2024E)	US$ 8.35 Billion
Forecasted Market Value (2034F)	US$ 29.64 Billion
Global Market Growth Rate (2024 to 2034)	13.5% CAGR
East Asia Market Share (2024E)	14.1%
North America Market Share (2024E)	37.3%
Sales of Body-Worn Patch Injectors (2024E)	US$ 7.12 Billion
Key Companies Profiled	West Pharmaceutical Services, Inc.; Bespak; Amgen Inc.; Insulet Corporation; Valeritas Inc.; Dexcom, Inc.; Ypsomed Group; Tandem Diabetes Care, Inc.; Becton, Dickinson and Company; MannKind Corporation.

Why are Wearable Injection Systems Being Increasingly Adopted in Chronic Disease Management?

“Patient-Centricity and Greater Focus on Human Factors in Drug Delivery Design”

Wearable injection systems are drug-delivery devices that attach to the body and automatically deliver predetermined doses to the patient at optimal times. Wearable injection systems are the logical progression of chronic disease management in a society where everything must happen instantly. The notion of patient-centricity and a heightened emphasis on human factors in drug-delivery design are key wearable injector market trends.

Development of delivery systems capable of handling high-viscosity solutions has been made necessary by the trend toward the use of biologics in pharmaceutical development. These circumstances have led to the emergence of wearable injection systems.

What Challenges Do Manufacturers Face in Adoption of Wearable Injectable Devices?

“High Cost of Wearable Injectable Drugs and Restricting Availability”

As technology advances, various drug delivery systems are being developed to make it easier for patients to receive medication efficiently and conveniently. Wearable injectable medications are significantly more expensive than auto-injectors and other injectors, such as pens. When it comes to administering insulin, there are a lot of options available besides less costly delivery systems such as standard prefilled syringes and insulin pens.

The public health system does not promote the use of wearable injectable devices. This is a result of the device's high cost, the paucity of reimbursement choices, and low patient awareness of the technology. The device's restricted availability adds yet another challenge for market players.

Country-wise Insights

Growth of the market in North America is driven by fueled by the rising interest in and adoption of such devices in the region. As wearable injectors are more expensive than other devices, the availability of reimbursement is projected to play an important role in fueling market growth. Government initiatives aimed at promoting the use of wearable injectors, rising healthcare costs, and an aging population are also contributing to the expansion of the wearable injector market size in the region.

How is the Healthcare System in the United States Supporting Wearable Injector Adoption?

“Reimbursements for Therapeutic Drug Delivery Making Wearable Injectors Accessible to More Patients”

Attribute	United States
Market Value (2024E)	US$ 2.77 Billion
Growth Rate (2024 to 2034)	9.7% CAGR
Projected Value (2034F)	US$ 6.99 Billion

The United States is estimated to hold 89.1% of the wearable injector market share in North America in 2024. Use of wearable injectors is increasing in the United States at a remarkable pace due to a well-established healthcare system and a rise in the prevalence of chronic diseases related to lifestyle choices. There is growing demand in the country due to the local presence of major market players in the United States, such as Becton, Dickinson and Company, and Johnson & Johnson Services, Inc. Reimbursements for therapeutic drug delivery are also driving market growth.

How is Introduction of C150 Category Driving Market Growth in Japan?

“C150 Category Simplifying Reimbursement Process and Improving Diabetes Care”

Attribute	Japan
Market Value (2024E)	US$ 400 Million
Growth Rate (2024 to 2034)	14.9% CAGR
Projected Value (2034F)	US$ 1.6 Billion

Japan is expected to account for 34% share of the East Asia market in 2024. Japan's medical insurance system has added a new category known as "C150." It includes all people with diabetes who meet the requirements to be eligible for financial aid in Japan for the purchase of the Dexcom G6 continuous glucose monitor (CGM). Everyone who injects themselves with insulin at least once a day is classified as falling into Japan's new C150 category.

Everyone who meets the requirements is covered, regardless of the type of diabetes they have. Hospitals are no longer required to apply for eligibility under the Japanese medical insurance program. The new category allows reimbursement to be received by all hospitals.

Category-wise Insights

Wearable infusion pumps or off-body injectors are small, lightweight devices that patients can wear on their belts with an attached cannula to the skin. They are estimated to occupy 14.7% market share in 2024. These enable patients to move freely throughout the course of treatment, making them perfect for those who need continuous or sporadic infusions over an extended period. With a tube connecting the pump to the infusion set that is positioned in the subcutaneous fatty tissue, the majority of insulin pumps are worn on belts.

How Do Body-Worn Patch Injectors Improve Subcutaneous Injection Administration?

“Body-Worn Injectors Effectively Handling Increasing Dosage Volumes and Viscosities”

Attribute	Body-Worn Patch Injector
Segment Value (2024E)	US$ 7.12 Billion
Growth Rate (2024 to 2034)	13.7% CAGR
Projected Value (2034F)	US$ 25.59 Billion

Body-worn patch injectors are set to hold a significant market share of 85.3% in 2024. Subcutaneous injections of biological and pharmaceutical therapies are carried out through the use of patch injectors worn on the body. Using an adhesive, the device is affixed to the patient's skin directly. Depending on the dimensions of the device, this adhesive surface can stretch to the size of a mobile phone's face.

These wearable injectors have the potential to successfully address the challenge of administering subcutaneous injections in non-clinical settings with increasing dosage volumes and viscosities. Body-worn wearable injectors effectively address the challenge of administering subcutaneous injections in non-clinical settings with increasing dosage volumes and viscosities.

Why are Retail Pharmacies Maintaining Substantial Market Share?

“Convenience in Obtaining and Using Diverse Wearable Injectors”

Attribute	Retail Pharmacies
Segment Value (2024E)	US$ 2.85 Billion
Growth Rate (2024 to 2034)	13.4% CAGR
Projected Value (2034F)	US$ 10.17 Billion

Retail pharmacies are poised to hold a market share of 34.7% in 2024. The retail pharmacies segment maintains a high market share due to the growing number of patients using ultra-large volumes of wearable injectors for various drug deliveries. It is simple to obtain and use a variety of wearable injectors because they are sold and used in retail pharmacies and drug stores. Retail pharmacies occupy a significant market share worldwide due to improved product accessibility and the ensuing increase in product adoption.

Competitive Landscape

Key players in the wearable injector market have been working together with industry and non-industry participants mainly for product and technology integration. In collaboration with manufacturers of delivery devices, drug developers are assessing innovative drug delivery methods for their drug candidates during preclinical phases.

• In May 2023, Viridian Therapeutics collaborated with Enable Injections to test its enFuse wearable injector technology for preclinical drug candidates. To meet the increasing market demand for on-body injectors, device developers are also working with contract manufacturing companies to release their products.
• In March 2023, Thermo Fisher Scientific and the Stevanato Group collaborated on a project wherein the former supplied pre-sterilized EZ-fill cartridges and assembly equipment, while the latter handled fill finish and final assembly.

Fact.MR provides detailed information about the price points of key providers of wearable injectors positioned across the world, sales growth, production capacity, and speculative technological expansion in this new market report.

Segmentation of Wearable Injector Market Research

• By Product Type :

  • Body-Worn Patch Injectors
  • Off-Body Worn Injectors

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa